₩ 117550
Key Takeaways
Risk factor
Resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of 000100.KS is 154773 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
